In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

EyeTel Imaging Inc.

Division of NeuroMetrix Inc.
www.eyetelimaging.com

Latest From EyeTel Imaging Inc.

Business and Technology Briefs

Brief summaries of recent product and company developments in the device industry, including: developments in cardiac stenting, DES competition heats up as the market stabilizes, and headaches for neuro device companies.
Medical Device

Deals Update (06/2007)

A roundup of recent medtech strategic alliances, mergers & acquisitions and financings.
Medical Device

Visible Progress in Devices for Age-Related Macular Degeneration

A mere seven years ago, before the approval of Visudyne photodynamic therapy, patients losing their vision to age-related macular degeneration (AMD) were told that there was nothing that could be done for them. Today, AMD sufferers may choose from an assortment of drug treatments. Genentech's Lucentis will reach almost $1 billion in sales in its first year on the market, analysts predict, and it doesn't claim to do anything except slow down the progression of the disease. Moreover, the drug does this better than first-generation anti-VEGF drug Macugen. And if those options aren't enough--and they're not--a handful of start-ups developing device-based therapies are making significant progress by applying some highly innovative approaches. ScyFIX, for example, is applying electrical stimulation to halt the effects of AMD and possibly repair the damage done. NeoVista is applying radiation therapy to the back of the eye, an approach that could serve as an alternative to Lucentis and other drugs based on growth factors, which require frequent injections into the eye. Retina Implant has developed an implantable microchip that will stimulate intact nerve cells in the retina to recreate the sense of sight.
Medical Device Combination Products

Devices for a Diabetes Epidemic

With an increasing emphasis on tight glycemic control in diabetes care, innovative devices could play a big role, but diabetes is a deceptively complex market. Innovative companies need to differentiate themselves, yet not venture too far outside existing industry dynamics. As the first real-time continuous glucose monitors come to market, a handful of start-ups hopes to be ready for the second generation. Many of these are taking a side excursion into the market for in-hospital glucose monitoring, once a sleepy market but now growing rapidly as outcomes data shows reduced mortality and morbidty in intensively managed hyperglycemic hospital patients.
Medical Device
See All

Company Information

  • Industry
  • Medical Devices
    • Diagnostic Imaging Equipment & Supplies
      • Digital Imaging
      • Pacs (Picture Archive & Communications Systems)
  • Therapeutic Areas
  • Ophthalmic
  • Alias(es)
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • NeuroMetrix Inc.
  • Senior Management
  • John C Garbarino, Pres. & CEO
    Keith G Frey, CFO
    Paula M Waddell, VP, Mktg.
    Kevin Quinn, VP, Bus. Dev.
  • Contact Info
  • EyeTel Imaging Inc.
    Phone: (301) 483-6167
    9130 Guilford Rd.
    Columbia, MD 21046-2581
    USA
UsernamePublicRestriction

Register